Charles Piller

I do think it is in cases. Just to be clear again, I think the use of image manipulation to move forward drugs in development, it definitely occurs, but it's not common. There are lots of problems in drug development, as I'm sure many of the people of you are listening to this, really know from their own experience or from observing the news. But in this case, it can be used in that way.

I do think it is in cases. Just to be clear again, I think the use of image manipulation to move forward drugs in development, it definitely occurs, but it's not common. There are lots of problems in drug development, as I'm sure many of the people of you are listening to this, really know from their own experience or from observing the news. But in this case, it can be used in that way.

I do think it is in cases. Just to be clear again, I think the use of image manipulation to move forward drugs in development, it definitely occurs, but it's not common. There are lots of problems in drug development, as I'm sure many of the people of you are listening to this, really know from their own experience or from observing the news. But in this case, it can be used in that way.

So let me give you an example. So something I write about a lot in the book is a And they developed an Alzheimer's drug called Simufilam. So it's a funny, generic-sounding name. This drug was meant to be a cure for Alzheimer's, or at least a drug that could show dramatic improvement in cognitive symptoms, which would be an amazing breakthrough.

So let me give you an example. So something I write about a lot in the book is a And they developed an Alzheimer's drug called Simufilam. So it's a funny, generic-sounding name. This drug was meant to be a cure for Alzheimer's, or at least a drug that could show dramatic improvement in cognitive symptoms, which would be an amazing breakthrough.

So let me give you an example. So something I write about a lot in the book is a And they developed an Alzheimer's drug called Simufilam. So it's a funny, generic-sounding name. This drug was meant to be a cure for Alzheimer's, or at least a drug that could show dramatic improvement in cognitive symptoms, which would be an amazing breakthrough.

So, for the last several years, there have been a series of developments showing that, number one, the basic science studies—these are the studies that are before you get a drug into development. You have these, as you know, basic science studies— that test things in the lab to see if the drug might be relatively safe and relatively effective in people.

So, for the last several years, there have been a series of developments showing that, number one, the basic science studies—these are the studies that are before you get a drug into development. You have these, as you know, basic science studies— that test things in the lab to see if the drug might be relatively safe and relatively effective in people.

So, for the last several years, there have been a series of developments showing that, number one, the basic science studies—these are the studies that are before you get a drug into development. You have these, as you know, basic science studies— that test things in the lab to see if the drug might be relatively safe and relatively effective in people.

And then you go through a series of other studies like these so-called phase one studies where it's just testing for safety. You don't want to give someone a drug that might be very harmful. So you test it in a small number of healthy people to pass that bar. And then you go into phase two and phase three trials, which tested in much larger numbers of people for both safety and for effectiveness.

And then you go through a series of other studies like these so-called phase one studies where it's just testing for safety. You don't want to give someone a drug that might be very harmful. So you test it in a small number of healthy people to pass that bar. And then you go into phase two and phase three trials, which tested in much larger numbers of people for both safety and for effectiveness.

And then you go through a series of other studies like these so-called phase one studies where it's just testing for safety. You don't want to give someone a drug that might be very harmful. So you test it in a small number of healthy people to pass that bar. And then you go into phase two and phase three trials, which tested in much larger numbers of people for both safety and for effectiveness.

So this is a company where literally for years it's been shown over and over again that the basic science experiments associated with their drug were apparently based on doctored images. And this was known by the funders, by the FDA, and by the general public because it was written about in the press by myself and many others.

So this is a company where literally for years it's been shown over and over again that the basic science experiments associated with their drug were apparently based on doctored images. And this was known by the funders, by the FDA, and by the general public because it was written about in the press by myself and many others.

So this is a company where literally for years it's been shown over and over again that the basic science experiments associated with their drug were apparently based on doctored images. And this was known by the funders, by the FDA, and by the general public because it was written about in the press by myself and many others.

Then, more recently, it was learned that even the clinical experimental data was cherry-picked and changed in its presentation by people within Cassava Sciences. And to make it look like the drawbook was being more effective than it really was in its Phase II studies, this proved to be instrumental in getting the FDA to permit it to go into Phase III studies.

Then, more recently, it was learned that even the clinical experimental data was cherry-picked and changed in its presentation by people within Cassava Sciences. And to make it look like the drawbook was being more effective than it really was in its Phase II studies, this proved to be instrumental in getting the FDA to permit it to go into Phase III studies.

Then, more recently, it was learned that even the clinical experimental data was cherry-picked and changed in its presentation by people within Cassava Sciences. And to make it look like the drawbook was being more effective than it really was in its Phase II studies, this proved to be instrumental in getting the FDA to permit it to go into Phase III studies.

But all along, the FDA, from its own inspectors, knew that there were problems with these data. They knew from press reports and from whistleblowers that there were problems in the basic science research. Apparently altered images left and right. Many, many examples of this. Even questions about the fundamental scientific idea behind the drug and how it was learned.

But all along, the FDA, from its own inspectors, knew that there were problems with these data. They knew from press reports and from whistleblowers that there were problems in the basic science research. Apparently altered images left and right. Many, many examples of this. Even questions about the fundamental scientific idea behind the drug and how it was learned.